Novavax Applies to WHO for Emergency Use Approval

Novavax Inc, and Serum Institute of India applied to the World Health Organization (WHO) for having the emergency use approval for their COVID-19 vaccine, Novavax, Reuters reported on Thursday.

The corporation highlighted that the earliest productions of the vaccine will be dedicated to poor, and medium-income countries as the rest of rich and developed countries are depending on a wide collection of other vaccines to secure their residents.

The WHO may back the vaccine to be shipped to several countries that depend on WHO guidance for their pandemic related measures.

In the same context, Novavax applied their documents to several countries to have a domestic approval of emergency use in them such as India, and Indonesia.

The latest approved COVID-19 vaccine by the international organization were the Chinese Sinopharm, and Sinovac. In a reported released by the advisory board of the WHO about Sinopharm, the group of experts assured the effectiveness of the two-dose vaccine for adults aged between 18 and 59 years old with 90%.

Until now, only seven COVID-19 vaccines have been approved for emergency use by the WHO. They are: Pfizer, Moderna, AstraZeneca, Johnson & Johnson, AstraZeneca, AstraZeneca's vaccine that manufactured in India Covidshield, Sinopharm, and Sinovac.

However, there are several effective lists that were not granted the WHO emergency use approval such as the Russian Sputnik V, and the Cuban Abdallah.